Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Knee replacement patients may regain muscle faster with amino acid supplement

NCT ID NCT07634523

Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking branched-chain amino acid (BCAA) supplements for three months after knee replacement surgery can help improve muscle mass and strength in patients with sarcopenia (age-related muscle loss). About 140 adults aged 40 to 100 will be randomly assigned to receive either BCAA granules or standard care. Researchers will measure muscle mass, grip strength, and physical function at 5 and 15 weeks after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Patients aged 40 to 100 years who are scheduled to undergo total knee arthroplasty. Exclusion Criteria: 1. Participants who used antiretroviral agents within 4 weeks before the first administration of Livact. 2. Participants who used medications associated with fatty liver within 4 weeks before the first administration of Livact, including thiazolidinediones, sodium glucose cotransporter 2 inhibitors, amiodarone, methotrexate, tamoxifen, valproate, or corticosteroids. 3. Participants who used branched chain amino acid products or multinutritional supplements within 4 weeks before the first administration of Livact. 4. Participants who used pain medications other than those prescribed for total knee arthroplasty treatment within 2 weeks before the first administration of Livact. 5. Participants with markedly decreased hepatic protein synthetic function. 6. Participants with congenital branched chain amino acid metabolism disorders. 7. Participants with hereditary galactose intolerance, Lapp lactase deficiency, or glucose galactose malabsorption. 8. Participants with a history of high tibial osteotomy. 9. Participants with neurologic diseases such as stroke or Parkinson disease. 10. Participants with gait disturbance due to causes other than arthritis. 11. Participants taking medication for spinal stenosis. 12. Participants with a history of hypersensitivity to the investigational product or its components. 13. Pregnant or breastfeeding participants. 14. Participants planning pregnancy during the trial or who have the possibility of pregnancy but do not agree to use appropriate contraception during the trial. 15. Participants judged by the investigator to be inappropriate for participation in the clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcopenia Total knee arthroplasty

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHA Bundang Medical Center

    ACTIVE_NOT_RECRUITING

    Seongnam-si, Gyeonggi-do, 13496, South Korea

  • Chung-Ang University Hospital

    RECRUITING

    Seoul, Seoul, 06973, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.